Published online before print April 25, 2007, doi:10.1212/01.wnl.0000260269.93245.d2)
NEUROLOGY 2007;68:1800-1808
© 2007 American Academy of Neurology
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial
ADAPT Research Group*
From Johns Hopkins Bayview and Johns Hopkins School of Medicine(G.G.L.), Baltimore; VA Puget Sound Health Care System and University of Washington (J.C.S.B.), Seattle; Boston University School of Medicine (R.C.G.), MA; Johns Hopkins Bloomberg School of Public Health (C.M.), Baltimore; Johns Hopkins School of Medicine (S.P.), Baltimore, MD; and Sun Health Research Institute (M.S.), Sun City, AZ.
Address correspondence and reprint requests to C.G. Lyketsos, Department of Psychiatry, Johns Hopkins Bayview, 5300 Alpha Commons Drive, 4th Floor, Baltimore, MD 21224 kostas{at}jhmi.edu
Objective: To evaluate the efficacy and safety of naproxen and celecoxib for the primary prevention of Alzheimer disease (AD).
Methods: Randomized, placebo-controlled, double-masked clinical trial conducted at six US dementia research clinics. Volunteers aged 70+ years, with cognitive screening scores above designated cut-offs and a family history of AD, were randomly assigned to celecoxib 200 mg BID, naproxen sodium 220 mg BID, or placebo. Enrollment began in early 2001. The main outcome measure was diagnosis of AD after randomization.
Results: On December 17, 2004, treatments were suspended. Events while on treatment yielded hazard ratios vs placebo of 1.99 (95% CI 0.80 to 4.97; p = 0.14) for celecoxib and 2.35 (0.95 to 5.77; p = 0.06) for naproxen. Imperfect screening measures led to enrollment of 7 individuals with dementia and 46 others with milder cognitive syndromes. Their (prevalent) illness was detected at enrollment and diagnosed within 6 months following randomization. Secondary analyses that excluded the 7 cases of prevalent dementia showed increased hazard ratios for AD with both treatments. Neither treatment produced a notable effect on the incidence of milder cognitive syndromes.
Conclusions: These results do not support the hypothesis that celecoxib or naproxen prevent Alzheimer dementia, at least within the early years after initiation of treatment. Masked long-term follow-up of these participants will be essential.
Received September 18, 2006. Accepted in final form January 21, 2007.
This article has been cited by other articles:
|
|
|
|
 
S. E. O'Bryant, S. C. Waring, V. Hobson, J. R. Hall, C. B. Moore, T. Bottiglieri, P. Massman, and R. Diaz-Arrastia
Decreased C-Reactive Protein Levels in Alzheimer Disease
J Geriatr Psychiatry Neurol,
March 1, 2010;
23(1):
49 - 53.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Ganguli and W. A. Kukull
Lost in Translation: Epidemiology, Risk, and Alzheimer Disease
Arch Neurol,
January 1, 2010;
67(1):
107 - 111.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Cimino, I. Sokal, J. Leverenz, Y. Fukui, and T. J. Montine
DOCK2 Is a Microglial Specific Regulator of Central Nervous System Innate Immunity Found in Normal and Alzheimer's Disease Brain
Am. J. Pathol.,
October 1, 2009;
175(4):
1622 - 1630.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.C.S. Breitner, S. J.P.A. Haneuse, R. Walker, S. Dublin, P. K. Crane, S. L. Gray, and E. B. Larson
Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort
Neurology,
June 2, 2009;
72(22):
1899 - 1905.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Bennett and R. A. Whitmer
NSAID exposure and risk of Alzheimer disease: Is timing everything?
Neurology,
June 2, 2009;
72(22):
1884 - 1885.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. K. Martin, J. Brandt, J. C. S. Breitner, S. Craft, D. Evans, R. Green, M. Mullan, S. Piantadosi, and C. Szekely
Can Treatment With Nonsteroidal Anti-inflammatory Drugs Protect From Dementia?--Reply
Arch Neurol,
April 1, 2009;
66(4):
540 - 540.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Coley, S. Andrieu, V. Gardette, S. Gillette-Guyonnet, C. Sanz, B. Vellas, and A. Grand
Dementia Prevention: Methodological Explanations for Inconsistent Results
Epidemiol. Rev.,
November 1, 2008;
30(1):
35 - 66.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sano, D. Jacobs, H. Andrews, K. Bell, N. Graff-Radford, J. Lucas, P. Rabins, K. Bolla, W.-Y. Tsai, P. Cross, et al.
A multi-center, randomized, double blind placebo-controlled trial of estrogens to prevent Alzheimer's disease and loss of memory in women: design and baseline characteristics
Clinical Trials,
October 1, 2008;
5(5):
523 - 533.
[Abstract]
[PDF]
|
|
|
|
|
|
|
ADAPT Research Group
Cognitive Function Over Time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): Results of a Randomized, Controlled Trial of Naproxen and Celecoxib
Arch Neurol,
July 1, 2008;
65(7):
896 - 905.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Szekely, R. C. Green, J.C.S. Breitner, T. Ostbye, A. S. Beiser, M. M. Corrada, H. H. Dodge, M. Ganguli, C. H. Kawas, L. H. Kuller, et al.
No advantage of A{beta}42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies
Neurology,
June 10, 2008;
70(24):
2291 - 2298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Arvanitakis, F. Grodstein, J. L. Bienias, J. A. Schneider, R. S. Wilson, J. F. Kelly, D. A. Evans, and D. A. Bennett
Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology
Neurology,
June 3, 2008;
70(23):
2219 - 2225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. C. Vlad, D. R. Miller, N. W. Kowall, and D. T. Felson
Protective effects of NSAIDs on the development of Alzheimer disease
Neurology,
May 6, 2008;
70(19):
1672 - 1677.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Kotilinek, M. A. Westerman, Q. Wang, K. Panizzon, G. P. Lim, A. Simonyi, S. Lesne, A. Falinska, L. H. Younkin, S. G. Younkin, et al.
Cyclooxygenase-2 inhibition improves amyloid-{beta}-mediated suppression of memory and synaptic plasticity
Brain,
March 1, 2008;
131(3):
651 - 664.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Patterson MD, J. W. Feightner MD MSc, A. Garcia MD PhD, G.-Y. R. Hsiung MD MHSc, C. MacKnight MD MSc, and A. D. Sadovnick PhD
Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease
Can. Med. Assoc. J.,
February 26, 2008;
178(5):
548 - 556.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. B. Gorelick and J. V. Bowler
Advances in Vascular Cognitive Impairment 2007
Stroke,
February 1, 2008;
39(2):
279 - 282.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Rogers and M. N. Sabbagh
Interactions of stroke, nonsteroidal anti-inflammatory drugs, and APOE status in dementia risk
Neurology,
January 1, 2008;
70(1):
5 - 6.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. P. Imbimbo, E. Del Giudice, D. Colavito, A. D'Arrigo, M. D. Carbonare, G. Villetti, F. Facchinetti, R. Volta, V. Pietrini, M. F. Baroc, et al.
1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic Acid (CHF5074), a Novel {gamma}-Secretase Modulator, Reduces Brain beta-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease without Causing Peripheral Toxicity
J. Pharmacol. Exp. Ther.,
December 1, 2007;
323(3):
822 - 830.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Inflammation Subsiding as a Suspect in Cognitive Disorders of Aging
Journal Watch Neurology,
August 14, 2007;
2007(814):
1 - 1.
[Full Text]
|
|
|
|
|
|
|
J. M. Scharf and K. R. Daffner
NSAIDs in the prevention of dementia: A Cache-22?
Neurology,
July 17, 2007;
69(3):
235 - 236.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Can NSAIDs Prevent Alzheimer Disease?
Journal Watch (General),
May 29, 2007;
2007(529):
1 - 1.
[Full Text]
|
|
|
|
